With Fed Chair Kevin Warsh signaling that interest rates may stay higher for longer, inflation still above the 2% target, and oil prices jumping after renewed tensions in the Strait of Hormuz, many investors are reassessing how reliable their income stocks really are. Dividend Aristocrats, with long records of raising payouts and a focus on financial discipline, can look appealing when volatility and inflation risks rise together. This article walks through 3 stocks from our Dividend Aristocrats screener that appear positively exposed to the latest Fed and energy headlines, helping you think about where income and resilience might still align.

Becton Dickinson (BDX)

Overview: Becton Dickinson develops and sells a broad range of medical supplies, devices, lab equipment, and diagnostic products used in hospitals, clinics, labs, and at home, covering everything from IV catheters and syringes to advanced diagnostics and surgical tools.

Operations: Becton Dickinson generates about US$11.5b from BD Medical (excluding BD Interventional) and US$5.4b from BD Interventional, with its largest market in the United States at roughly US$13.1b.

Market Cap: US$42.4b

Becton Dickinson stands out in a higher for longer rate world because it pairs a long dividend growth history with a large, consumables heavy medtech portfolio that often sits at the core of everyday clinical workflows. The company is working to improve margins through its BD Excellence program while rolling out products like the CentroVena One insertion system and expanding in areas such as biologics delivery and pharmacy automation, all supported by continued share buybacks. At the same time, investors need to weigh high debt, a recent US$1.3b one off loss, product recalls, and ongoing inflation and trade pressures. How those positives and risks stack up for Becton Dickinson, especially after the recent pullback, is where the real story begins.

Becton Dickinson’s consumables engine, margin work and buybacks may be pointing in one direction, while its high debt, recalls and that recent US$1.3b loss hint at another. See how the full picture lines up in the 5 key rewards and 2 important warning signs

Cigna Group (CI)

Overview: The Cigna Group is a large US health insurer and services company that provides medical coverage, pharmacy benefits, and related health solutions to employers, individuals, and globally mobile workers through its Evernorth Health Services and Cigna Healthcare segments.

Operations: Cigna generates the bulk of its revenue from Evernorth Health Services at about US$239.7b, with Cigna Healthcare contributing roughly US$44.3b and Other Operations about US$0.6b, partly offset by a US$6.8b loss in Corporate and Other Operations.

Market Cap: US$80.6b

Cigna Group gives income focused investors a mix of large cap scale, Dividend Aristocrat credentials, and health services exposure that can hold up when higher for longer rates and inflation worries keep markets on edge. Evernorth’s pharmacy benefit and specialty operations sit at the heart of efforts to control drug and medical costs. Recent AI driven Pharmacy Forward initiatives show the company focusing on efficiency and patient adherence. At the same time, high leverage, regulatory scrutiny of pharmacy benefit managers, and management’s relatively short tenure mean the story is not risk free. The interaction between cash flows, valuation signals, and policy pressures is where Cigna starts to look particularly interesting for long term dividend portfolios.

Cigna’s scale in health services and Dividend Aristocrat status could be masking a more complex trade off between cash generation and policy risk. Get the fuller story in the 5 key rewards and 1 important warning sign

STERIS (STE)

Overview: STERIS is a healthcare equipment and services company that helps hospitals, pharmaceutical manufacturers, and life sciences firms prevent infections, supplying cleaning chemicals, sterilizers and washers, endoscopy and surgical room equipment, and ongoing maintenance and outsourced sterilization services worldwide.

Operations: STERIS generates about US$4.2b from Healthcare, US$1.1b from Applied Sterilization Technologies, and US$0.6b from Life Sciences, with roughly US$4.3b of revenue from the United States, US$1.5b from other international markets, and about US$108.5m from Ireland.

Market Cap: US$21.2b

STERIS offers investors a mix of recurring consumables and services, capital equipment tied to infection prevention, and a record of dividend growth that can look attractive when higher for longer rates and energy driven inflation keep markets on edge. Earnings and margins have recently moved higher, supported by solid Healthcare and Life Sciences demand. A sizeable buyback program and disciplined management pay add to the income and capital return story. The other side of the coin is sensitivity to tariffs and metal costs, ongoing healthcare reimbursement pressures, and reliance on acquisitions and bioprocessing customers, which can all influence growth and cash conversion. How those supports and pressure points balance out is where the case for STERIS really becomes interesting for dividend focused investors.

STERIS’s mix of recurring consumables, capital equipment and dividend growth hints at a story that many income investors may be only half seeing. The real tension sits in the 4 key rewards and 1 important warning sign

The three Dividend Aristocrats covered here are only a starting point, with our full Dividend Aristocrats screener surfacing 32 more large and established companies that pair long dividend track records with income and stability stories that might be just as compelling. Use Simply Wall St to identify and analyze the specific catalysts, financial health filters, and dividend narratives that matter most to you so you can focus on the highest conviction ideas for your portfolio.

Take Control of Your Investment Journey

If STERIS or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before They Fly?

New ideas can move from under the radar to fully priced faster than many expect, especially when momentum builds and sentiment shifts. Scan fresh stock baskets before the crowd and consider them early.

• Explore reliable income streams while rates stay elevated by scanning a curated group of higher yield companies described as 8 dividend fortresses so you are not caught searching after payouts drop.
• Track where real AI revenues meet discipline by reviewing 63 profitable AI stocks that aren't just burning cash before expectations run too hot and you are left watching the strongest operators from the sidelines.
• Review potential opportunities linked to infrastructure spending cycles by filtering 34 power grid technology and infrastructure stocks and identify possible beneficiaries of grid upgrades while these ideas remain less widely followed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.